Roche Holding AG (RHHBY)
| Previous Close | 31.60 |
| Open | 31.61 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 31.19 - 31.68 |
| 52 Week Range | 29.20 - 40.48 |
| Volume | |
| Avg. Volume | 2,974,534 |
| Market Cap | 202.42B |
| Beta (5Y Monthly) | 0.16 |
| PE Ratio (TTM) | 16.22 |
| EPS (TTM) | 1.93 |
| Earnings Date | Jul 25, 2024 |
| Forward Dividend & Yield | 1.35 (4.27%) |
| Ex-Dividend Date | Mar 14, 2024 |
| 1y Target Est | 37.86 |
GlobeNewswireFDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Priority Review recognises the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options1,2Additional analyses of INAVO120 will be presented in an oral abstract session at the 2024 American Society of Clinical Oncology Annual MeetingThe target action date for the FDA decision is 27 November, 2024 Basel, 29 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s New
Business WireFDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
SOUTH SAN FRANCISCO, Calif., May 29, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application and granted Priority Review to inavolisib, an investigational oral therapy, in combination with palbociclib (Ibrance®) and fulvestrant. The inavolisib-based regimen was evaluated in adult patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth fa
PR NewswireRoche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing
Roche announced today that Hitachi High-Tech and Roche have extended their partnership, committing to at least 10 years of additional collaboration. Bringing together the companies' expertise and track record in diagnostics innovation, engineering and manufacturing, the renewed contract further strengthens the two companies' long lasting partnership.
